|
ES2845212T3
(es)
|
2009-04-13 |
2021-07-26 |
Inst Nat Sante Rech Med |
Partículas de HPV y usos de las mismas
|
|
WO2014117121A1
(en)
|
2013-01-28 |
2014-07-31 |
St. Jude Children's Research Hospital, Inc. |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
EP4059521A1
(en)
|
2013-09-18 |
2022-09-21 |
Aura Biosciences, Inc. |
Virus-like particle conjugates for diagnosis and treatment of tumors
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
MX377283B
(es)
|
2013-11-21 |
2025-03-07 |
Ucl Business Ltd |
Célula t o nk que coexpresa un receptor antigénico quimérico (car).
|
|
RU2701346C1
(ru)
|
2013-12-06 |
2019-09-25 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
|
|
AU2014368892B2
(en)
|
2013-12-20 |
2019-06-13 |
Fred Hutchinson Cancer Center |
Tagged chimeric effector molecules and receptors thereof
|
|
US11885806B2
(en)
|
2014-03-05 |
2024-01-30 |
Autolus Limited |
Method for depleting malignant T-cells
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
AU2015243849B2
(en)
|
2014-04-10 |
2020-12-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Transgene genetic tags and methods of use
|
|
KR102211120B1
(ko)
|
2014-05-15 |
2021-02-03 |
내셔널 유니버시티 오브 싱가포르 |
변형된 천연 살해 세포 및 그의 용도
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
GB201415347D0
(en)
*
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
JP2018504104A
(ja)
*
|
2014-12-17 |
2018-02-15 |
セレクティスＣｅｌｌｅｃｔｉｓ |
非Ｔ細胞伝達ドメインを発現する阻害性キメラ抗原受容体（ｉＣＡＲまたはＮ−ＣＡＲ）
|
|
IL301458A
(en)
*
|
2014-12-24 |
2023-05-01 |
Autolus Ltd |
A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD
|
|
WO2016120218A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
|
|
EP3250611B1
(en)
*
|
2015-01-26 |
2021-04-21 |
The University of Chicago |
Car t-cells recognizing cancer-specific il 13r-alpha2
|
|
US10765699B2
(en)
|
2015-02-06 |
2020-09-08 |
National University Of Singapore |
Methods for enhancing efficacy of therapeutic immune cells
|
|
EP3261651B1
(en)
*
|
2015-02-27 |
2022-05-04 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
EP3286225B1
(en)
*
|
2015-04-23 |
2020-07-01 |
Baylor College of Medicine |
Cd5 chimeric antigen receptor for adoptive t cell therapy
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507108D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
WO2016176652A2
(en)
*
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
GB201507368D0
(en)
*
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
AU2016265845B2
(en)
*
|
2015-05-15 |
2020-10-08 |
City Of Hope |
Chimeric antigen receptor compositions
|
|
MA43344A
(fr)
*
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics Inc |
Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
|
|
GB201509413D0
(en)
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
CN107709552B
(zh)
*
|
2015-06-10 |
2022-05-13 |
南克维斯特公司 |
用于治疗癌症的修饰的nk-92细胞
|
|
TW202444897A
(zh)
*
|
2015-06-25 |
2024-11-16 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
JP7162530B2
(ja)
*
|
2015-08-07 |
2022-10-28 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
|
|
GB201514874D0
(en)
*
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
WO2017058850A1
(en)
|
2015-09-28 |
2017-04-06 |
Regents Of The University Of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
|
|
GB201518817D0
(en)
*
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
CN108473950A
(zh)
*
|
2015-10-30 |
2018-08-31 |
美国政府卫生与公众服务部 |
靶向癌症治疗
|
|
GB201519900D0
(en)
*
|
2015-11-11 |
2015-12-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CA3016287A1
(en)
*
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US11400116B2
(en)
|
2016-05-06 |
2022-08-02 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
US10222369B2
(en)
*
|
2016-05-17 |
2019-03-05 |
Chimera Bioengineering, Inc. |
Methods for making novel antigen binding domains
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
CA3035615A1
(en)
*
|
2016-09-02 |
2018-03-08 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duocars
|
|
CN107893052B
(zh)
*
|
2016-09-09 |
2023-11-03 |
科济生物医药（上海）有限公司 |
融合蛋白及其应用
|
|
WO2018064602A1
(en)
*
|
2016-09-30 |
2018-04-05 |
Baylor College Of Medicine |
Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
|
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
AU2017357649A1
(en)
*
|
2016-11-11 |
2019-05-23 |
Autolus Limited |
Chimeric antigen receptor
|
|
US11440958B2
(en)
|
2016-11-22 |
2022-09-13 |
National University Of Singapore |
Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
|
|
US11408005B2
(en)
|
2016-12-12 |
2022-08-09 |
Seattle Children's Hospital |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
CA3048648A1
(en)
*
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
T cells expressing a chimeric antigen receptor
|
|
JP2020506700A
(ja)
*
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
|
|
WO2018182511A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
IL269553B2
(en)
|
2017-03-27 |
2025-10-01 |
Nat Univ Singapore |
Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
|
|
CA3059882A1
(en)
|
2017-04-12 |
2018-10-18 |
Aura Biosciences, Inc. |
Targeted combination therapy
|
|
BR112019023608A2
(pt)
*
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
JP7132249B2
(ja)
*
|
2017-05-15 |
2022-09-06 |
オートラス リミテッド |
キメラ抗原受容体（ｃａｒ）を含む細胞
|
|
GB201707779D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
GB201707783D0
(en)
*
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
US20210130775A1
(en)
*
|
2017-08-02 |
2021-05-06 |
Autolus Limited |
Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
|
|
CN111247241A
(zh)
|
2017-08-10 |
2020-06-05 |
新加坡国立大学 |
T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法
|
|
JP2020535814A
(ja)
|
2017-09-28 |
2020-12-10 |
インパクト−バイオ リミテッド |
阻害性キメラ抗原受容体（ｉＣＡＲ）を調製するための普遍的プラットフォーム
|
|
US11905528B2
(en)
*
|
2017-10-12 |
2024-02-20 |
Icell Gene Therapeutics Inc. |
Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof
|
|
GB201717524D0
(en)
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
WO2019084240A1
(en)
|
2017-10-25 |
2019-05-02 |
Actinium Pharmaceuticals, Inc. |
METHODS OF TREATING CANCER USING RADIO-labeled CD45 ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELLULAR THERAPIES
|
|
MX2020004572A
(es)
|
2017-11-01 |
2020-10-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
|
|
CN111801348A
(zh)
|
2018-02-09 |
2020-10-20 |
新加坡国立大学 |
活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
GB201803079D0
(en)
*
|
2018-02-26 |
2018-04-11 |
Autolus Ltd |
Cell
|
|
WO2019177986A1
(en)
*
|
2018-03-12 |
2019-09-19 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
EP3790629A1
(en)
|
2018-05-11 |
2021-03-17 |
CRISPR Therapeutics AG |
Methods and compositions for treating cancer
|
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
|
AU2019269118B2
(en)
|
2018-05-15 |
2025-02-27 |
Autolus Limited |
Chimeric antigen receptor
|
|
EP3784776A4
(en)
|
2018-05-23 |
2022-01-26 |
National University of Singapore |
Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
GB201813178D0
(en)
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
FI3856775T3
(fi)
|
2018-09-27 |
2024-12-04 |
Autolus Ltd |
Kimeerinen antigeenireseptori
|
|
JP2022512594A
(ja)
*
|
2018-10-05 |
2022-02-07 |
ザンクト アンナ キンダークレプスフォルシュング |
キメラ抗原受容体（ｃａｒ）の群
|
|
EP3632461A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
JP2022504191A
(ja)
*
|
2018-10-05 |
2022-01-13 |
ザンクト アンナ キンダークレプスフォルシュング |
キメラ抗原受容体（ｃａｒ）群
|
|
EP3632460A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201816522D0
(en)
|
2018-10-10 |
2018-11-28 |
Autolus Ltd |
Methods and reagents for analysing nucleic acids from single cells
|
|
SG11202104188VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
US11793834B2
(en)
|
2018-12-12 |
2023-10-24 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
US20220133791A1
(en)
|
2019-01-23 |
2022-05-05 |
Miltenyi Biotec B.V. & Co. KG |
A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
WO2020180882A1
(en)
|
2019-03-05 |
2020-09-10 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
CN113543792A
(zh)
|
2019-03-08 |
2021-10-22 |
奥托路斯有限公司 |
包含工程化嵌合抗原受体和car调节剂的组合物和方法
|
|
GB201903237D0
(en)
|
2019-03-08 |
2019-04-24 |
Autolus Ltd |
Method
|
|
WO2020223445A1
(en)
|
2019-04-30 |
2020-11-05 |
Senti Biosciences, Inc. |
Chimeric receptors and methods of use thereof
|
|
AU2020265652A1
(en)
|
2019-04-30 |
2021-12-02 |
Atara Biotherapeutics, Inc. |
Antigen specific CD19-targeted CAR-T cells
|
|
MX2021013218A
(es)
|
2019-05-01 |
2021-12-10 |
Pact Pharma Inc |
Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
|
|
CN114450395A
(zh)
*
|
2019-05-16 |
2022-05-06 |
华盛顿大学 |
Lockr介导的car t细胞募集
|
|
GB201909144D0
(en)
|
2019-06-25 |
2019-08-07 |
Autolus Ltd |
Culture medium
|
|
WO2021009510A1
(en)
|
2019-07-16 |
2021-01-21 |
Autolus Limited |
Method for preconditioning a subject who is about to receive a t-cell therapy
|
|
GB201910185D0
(en)
|
2019-07-16 |
2019-08-28 |
Autolus Ltd |
Method
|
|
EP4017510A4
(en)
*
|
2019-08-20 |
2023-11-22 |
Senti Biosciences, Inc. |
CHIMERIC INHIBITOR RECEPTOR
|
|
WO2021044213A2
(en)
*
|
2019-09-05 |
2021-03-11 |
Migal-galilee Research Institute Ltd. |
Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
|
|
EP4031583A4
(en)
*
|
2019-09-16 |
2023-11-15 |
Fred Hutchinson Cancer Center |
CHIMERIC RECEPTOR PROTEINS AND THEIR USES
|
|
US20240122979A1
(en)
*
|
2019-10-08 |
2024-04-18 |
Provincial Health Services Authority |
Chimeric Cytokine Receptors
|
|
US20220411535A1
(en)
*
|
2019-11-26 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for upregulating hla class i on tumor cells
|
|
KR20220104217A
(ko)
|
2019-11-26 |
2022-07-26 |
노파르티스 아게 |
Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
|
|
WO2021119489A1
(en)
|
2019-12-11 |
2021-06-17 |
A2 Biotherapeutics, Inc. |
Lilrb1-based chimeric antigen receptor
|
|
CN115066249A
(zh)
|
2020-02-04 |
2022-09-16 |
美天施生物科技有限两合公司 |
表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
|
|
EP4107174A4
(en)
*
|
2020-02-20 |
2024-10-30 |
Senti Biosciences, Inc. |
ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
|
|
CN115397845A
(zh)
*
|
2020-02-20 |
2022-11-25 |
森迪生物科学公司 |
抑制性嵌合受体架构
|
|
GB202007044D0
(en)
|
2020-05-13 |
2020-06-24 |
Autolus Ltd |
Method
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
GB202008957D0
(en)
|
2020-06-12 |
2020-07-29 |
Autolus Ltd |
Culture medium
|
|
CN116490518A
(zh)
|
2020-07-17 |
2023-07-25 |
西穆尔克斯股份有限公司 |
用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法
|
|
EP4097486A4
(en)
|
2020-08-20 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF POSITIVE CANCERS AT CEACAM
|
|
WO2022040454A1
(en)
*
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
EP4058474B1
(en)
|
2020-08-20 |
2024-05-08 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
JP2023540339A
(ja)
*
|
2020-09-04 |
2023-09-22 |
インパクト バイオ ユーエスエー インコーポレイテッド |
癌治療に使用するためのバイシストロン性阻害性キメラ抗原受容体（ｉＣＡＲ）／活性化キメラ抗原受容体（ａＣＡＲ）構築物
|
|
WO2022061272A1
(en)
|
2020-09-21 |
2022-03-24 |
A2 Biotherapeutics, Inc. |
Engineered immune cells
|
|
WO2022081975A1
(en)
*
|
2020-10-15 |
2022-04-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inhibition of natural killer cell receptors
|
|
EP4240404A1
(en)
|
2020-11-09 |
2023-09-13 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
US11473060B2
(en)
|
2020-12-30 |
2022-10-18 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into NK cells
|
|
WO2022177979A1
(en)
|
2021-02-16 |
2022-08-25 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating her2 positive cancers
|
|
CA3172530A1
(en)
|
2021-02-25 |
2022-09-01 |
Spencer PARK |
Ror1 targeting chimeric antigen receptor
|
|
WO2022251377A1
(en)
*
|
2021-05-26 |
2022-12-01 |
Board Of Regents, The University Of Texas System |
Inhibitory chimeric antigen receptor prevents on-target off-tumor effects of adoptive cell therapy
|
|
US20240336903A1
(en)
*
|
2021-08-19 |
2024-10-10 |
Shandong Boan Biotechnology Co., Ltd. |
Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
|
|
GB202112923D0
(en)
|
2021-09-10 |
2021-10-27 |
Ucl Business Ltd |
Binding domain
|
|
EP4413031A1
(en)
|
2021-10-06 |
2024-08-14 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
EP4522204A1
(en)
|
2022-05-11 |
2025-03-19 |
Autolus Limited |
Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
|
|
GB202209920D0
(en)
|
2022-07-06 |
2022-08-17 |
Autolus Ltd |
Cell
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
EP4520346A1
(en)
|
2023-09-06 |
2025-03-12 |
Gyncentrum Sp. z o.o. |
Cells, methods and systems for use in the treatment of a cancer with dual-car-t
|
|
GB202403564D0
(en)
|
2024-03-12 |
2024-04-24 |
Autolus Ltd |
Method
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
NL2037929B1
(en)
|
2024-06-11 |
2026-01-12 |
Prinses Maxima Centrum Voor Kinderoncologie B V |
Brain Organoid
|